The R753Q polymorphism abrogates toll-like receptor 2 signaling in response to human cytomegalovirus

Clinical Infectious Diseases

Volumn 49, Issue 9, 2009, Pages

  Brown, Robert A ^a   Gralewski, Jonathon H ^a   Razonable, Raymund R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN B; TOLL LIKE RECEPTOR 2;

ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DNA POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

BLOTTING, WESTERN; CELL LINE; CYTOMEGALOVIRUS; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; INTERLEUKIN-8; NF-KAPPA B; POLYMORPHISM, GENETIC; TOLL-LIKE RECEPTOR 2; VIRAL PROTEINS;

EID: 72849107874     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/644501     Document Type: Article

References (15)

1. Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003; 16:637-646
2. Boehme KW, Guerrero M, Compton T. Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J Immunol 2006; 177:7094-7102
3. Compton T, Kurt-Jones EA, Boehme KW, et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol 2003; 77:4588-4596
4. Szomolanyi-Tsuda E, Liang X, Welsh RM, Kurt-Jones EA, Finberg RW. Role for TLR2 in NK cell-mediated control of murine cytomegalovirus in vivo. J Virol 2006; 80:4286-4291
5. Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 2007; 44:1315-1320
6. Razonable RR, Henault M, Lee LN, et al. Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure ismediated by coactivation of toll-like receptors 1 and 2. Antimicrob Agents Chemother 2005; 49:1617-1621
7. Razonable RR, Henault M, Paya CV. Stimulation of toll-like receptor 2 with bleomycin results in cellular activation and secretion of pro-inflammatory cytokines and chemokines. Toxicol Appl Pharmacol 2006; 210:181-189
8. Brant KA, Fabisiak JP. Nickel alterations of TLR2-dependent chemokine profiles in lung fibroblasts are mediated by COX-2. Am J Respir Cell Mol Biol 2008; 38:591-599
9. Texereau J, Chiche JD, Taylor W, Choukroun G, Comba B, Mira JP. The importance of Toll-like receptor 2 polymorphisms in severe infections. Clin Infect Dis 2005; 41(Suppl 7):S408-15.
10. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000; 68:6398-6401
11. Ogus AC, Yoldas B, Ozdemir T, et al. The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 2004; 23:219-223
12. von Aulock S, SchroderNW, Traub S, et al. Heterozygous toll-like receptor 2 polymorphism does not affect lipoteichoic acid-induced chemokine and inflammatory responses. Infect Immun 2004; 72:1828-1831
13. Schwartz DA, Cook DN. Polymorphisms of the Toll-like receptors and human disease. Clin Infect Dis 2005; 41(Suppl 7):S403-7.
14. Schroder NW, Diterich I, Zinke A, et al. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J Immunol 2005; 175:2534-2540
15. Schroder NW, Eckert J, Stubs G, Schumann RR. Immune responses induced by spirochetal outer membrane lipoproteins and glycolipids. Immunobiology 2008; 213:329-340